Published in Int J Environ Res Public Health on March 21, 2014
Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease. Genome Biol (2015) 1.00
Prevalence of Genes of OXA-23 Carbapenemase and AdeABC Efflux Pump Associated with Multidrug Resistance of Acinetobacter baumannii Isolates in the ICU of a Comprehensive Hospital of Northwestern China. Int J Environ Res Public Health (2015) 0.78
Isolation and Genetic Analysis of Multidrug Resistant Bacteria from Diabetic Foot Ulcers. Front Microbiol (2016) 0.78
The prevalence of aminoglycoside-modifying enzyme and virulence genes among enterococci with high-level aminoglycoside resistance in Inner Mongolia, China. Braz J Microbiol (2016) 0.77
Characterization of aminoglycoside resistance and virulence genes among Enterococcus spp. isolated from a hospital in China. Int J Environ Res Public Health (2015) 0.75
Liofilchem(®) Chromatic VRE and vancomycin MIC Test Strip detected glycopeptide resistance in a vanB neonatal Enterococcus faecium isolate showing alternate vancomycin susceptibility and resistance with bioMérieux Vitek2. Int J Clin Exp Pathol (2014) 0.75
Distribution of Integrons and Phylogenetic Groups among Enteropathogenic Escherichia coli Isolates from Children <5 Years of Age in Delhi, India. Front Microbiol (2017) 0.75
Environmental waters as a source of antibiotic-resistant Enterococcus species in Belgrade, Serbia. Environ Monit Assess (2015) 0.75
Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother (1993) 6.28
Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis (2002) 6.03
Vancomycin-resistant enterococci. Clin Microbiol Rev (2000) 5.61
Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg Infect Dis (1998) 4.84
The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol (2012) 4.64
Predominant pathogens in hospital infections. J Antimicrob Chemother (1992) 3.79
Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 3.58
Glycopeptide resistance in enterococci. Trends Microbiol (1996) 3.42
Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol Rev (1996) 3.29
Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol Rev (2008) 2.71
Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis (2001) 2.46
Quinupristin-dalfopristin-resistant Enterococcus faecium on chicken and in human stool specimens. N Engl J Med (2001) 2.32
Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect (2010) 1.94
Enterococcal infections & antimicrobial resistance. Indian J Med Res (2008) 1.89
Beta-lactam antibiotic resistance: a current structural perspective. Curr Opin Microbiol (2005) 1.89
Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther (2008) 1.80
Aminoglycoside resistance in enterococci. Clin Infect Dis (2000) 1.65
The effect of reserpine, an inhibitor of multi-drug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin. J Antimicrob Chemother (1997) 1.63
Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine. Antimicrob Agents Chemother (1999) 1.63
Mechanisms of resistance to quinupristin-dalfopristin among isolates of Enterococcus faecium from animals, raw meat, and hospital patients in Western Europe. Antimicrob Agents Chemother (2000) 1.61
Intrinsic and acquired resistance mechanisms in enterococcus. Virulence (2012) 1.59
Occurrence and spread of antibiotic resistances in Enterococcus faecium. Int J Food Microbiol (2003) 1.55
Macrolide resistance genes in Enterococcus spp. Antimicrob Agents Chemother (2000) 1.48
The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother (1999) 1.39
Prodigious substrate specificity of AAC(6')-APH(2"), an aminoglycoside antibiotic resistance determinant in enterococci and staphylococci. Chem Biol (1999) 1.20
A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob Agents Chemother (2000) 1.19
Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis (2003) 1.19
Bacterial resistance surveillance in China: a report from Mohnarin 2004-2005. Eur J Clin Microbiol Infect Dis (2008) 1.14
Characterization of macrolide resistance in Gram-positive cocci from Colombian hospitals: a countrywide surveillance. Int J Infect Dis (2007) 1.13
Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan. Antimicrob Agents Chemother (2000) 1.09
High-frequency recovery of quinupristin-dalfopristin-resistant Enterococcus faecium isolates from the poultry production environment. J Clin Microbiol (2001) 1.04
Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis (2000) 1.00
Reducing the spread of antimicrobial-resistant microorganisms. Control of vancomycin-resistant enterococci. Pediatr Clin North Am (1995) 1.00
Species prevalence and antibacterial resistance of enterococci isolated in Kuwait hospitals. J Med Microbiol (2003) 0.98
Prevalence and antimicrobial resistance pattern of multidrug-resistant enterococci isolated from clinical specimens. Indian J Med Microbiol (2012) 0.97
Antimicrobial-resistant enterococci in animals and meat: a human health hazard? Foodborne Pathog Dis (2010) 0.97
Antimicrobial susceptibility testing by the Kirby-Bauer disc diffusion method. Ann Clin Lab Sci (1973) 0.96
High-level Aminoglycoside Resistance and Reduced Susceptibility to Vancomycin in Nosocomial Enterococci. J Glob Infect Dis (2010) 0.94
High rate of resistance to quinupristin-dalfopristin in Enterococcus faecium clinical isolates from Korea. Antimicrob Agents Chemother (2005) 0.86
Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother (2003) 0.84
Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates. J Antimicrob Chemother (1997) 0.83
Antimicrobial susceptibility of enterococci in vitro. J Formos Med Assoc (1993) 0.80
Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. Transpl Infect Dis (2003) 0.80
Distribution of enterococci in Hong Kong. J Infect (2002) 0.80
Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. Am Fam Physician (2001) 0.80
Antimicrobial resistance from enterococci in a pediatric hospital. Plasmids in Enterococcus faecalis isolates with high-level gentamicin and streptomycin resistance. Arch Med Res (2001) 0.80
Antimicrobial resistance of Enterococcus sp. isolated from the intestinal tract of patients from a university hospital in Brazil. Mem Inst Oswaldo Cruz (2005) 0.79
Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections. J Antimicrob Chemother (1999) 0.79
Presence of macrolide resistance genes in streptococci and enterococci isolated from pigs and pork carcasses. Int J Food Microbiol (2003) 0.78
Quinupristin-Dalfopristin. Curr Infect Dis Rep (1999) 0.77